DOES BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUG NAIVE VERSUS NON-NAIVE PATIENTS WITH INFLAMMATORY JOINT DISEASES HAVE SIMILAR GOLIMUMAB DRUG SURVIVAL AND EFFICACY? DATA FROM THE PROSPECTIVE OBSERVATIONAL NOR-DMARD STUDY

被引：0
|
作者：
Michelsen, B. [1 ,2 ]
Sexton, J. [1 ]
Kvien, T. K. [1 ]
机构：
[1] Diakonhjemmet Hosp, Dept Rheumatol, Oslo, Norway
[2] Hosp Southern Norway Trust, Kristiansand, Norway
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.1885
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0264
引用
收藏
页码：995 / 996
页数：2
相关论文
共 15 条
  • [1] Serum golimumab concentration and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR-DMARD study
    Gehin, J. E.
    Warren, D. J.
    Syversen, S. W.
    Lie, E.
    Sexton, J.
    Loli, L.
    Wierod, A.
    Bjoro, T.
    Kvien, T. K.
    Bolstad, N.
    Goll, G. L.
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2021, 50 (06) : 445 - 454
  • [2] SERUM GOLIMUMAB CONCENTRATIONS AND ANTI-DRUG ANTIBODIES ARE ASSOCIATED WITH TREATMENT RESPONSE AND DRUG SURVIVAL IN PATIENTS WITH INFLAMMATORY JOINT DISEASES: DATA FROM THE NOR-DMARD STUDY
    Gehin, J. E.
    Warren, D. J.
    Syversen, S. W.
    Lie, E.
    Sexton, J.
    Loli, L.
    Wierod, A.
    Bjoro, T.
    Kvien, T. K.
    Bolstad, N.
    Goll, G. L.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 864 - 865
  • [3] Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study
    Gehin, Johanna Elin
    Goll, Guro Lovik
    Warren, David John
    Syversen, Silje Watterdal
    Sexton, Joseph
    Strand, Eldri Kveine
    Kvien, Tore Kristian
    Bolstad, Nils
    Lie, Elisabeth
    [J]. ARTHRITIS RESEARCH & THERAPY, 2019, 21 (01)
  • [4] Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study
    Johanna Elin Gehin
    Guro Løvik Goll
    David John Warren
    Silje Watterdal Syversen
    Joseph Sexton
    Eldri Kveine Strand
    Tore Kristian Kvien
    Nils Bolstad
    Elisabeth Lie
    [J]. Arthritis Research & Therapy, 21
  • [5] Primary 1-Year Data of Ixekizumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naive Patients with Radiographic Axial Spondyloarthritis Including Data in Patients Rerandomized from Adalimumab to Ixekizumab
    Wei, Cheng-Chung
    Gensler, Lianne
    Walsh, Jessica
    Landewe, Robert B. M.
    Tomita, Tetsuya
    Zhao, Fangyi
    Gallo, Gaia
    Carlier, Hilde
    Dougados, Maxime
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [6] The efficacy and safety of ixekizumab, adalimumab, and placebo in patients with psoriatic arthritis naive to biological disease-modifying anti-rheumatic drugs: a double-blind phase 3 study
    Mease, P.
    van der Heijde, D.
    Ritchlin, C.
    Cuchacovich, R.
    Shuler, C.
    Lin, C-Y
    Vangerow, H.
    Samanta, S.
    Lee, C. H.
    Gladman, D.
    Larsson, E.
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2016, 45 : 31 - 33
  • [7] ANTI-DRUG ANTIBODIES TO CERTOLIZUMAB PEGOL ARE ASSOCIATED WITH LOW DRUG LEVELS AND REDUCED CLINICAL RESPONSE AT 3 MONTHS IN PATIENTS WITH INFLAMMATORY JOINT DISEASES. DATA FROM THE NOR-DMARD STUDY.
    Gehin, J. E.
    Goll, G. L.
    Warren, D. J.
    Syversen, S. W.
    Sexton, J.
    Strand, E. K.
    Kvien, T. K.
    Bolstad, N.
    Lie, E.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 844 - 844
  • [8] Real-world effectiveness of a single conventional disease-modifying anti-rheumatic drug (cDMARD) plus an anti-TNF agent versus multiple cDMARDs in rheumatoid arthritis: a prospective observational study
    So, Min Wook
    Kim, Sang-Hyon
    Kim, Dong Wook
    Sung, Yoon-Kyoung
    Choe, Jung-Yoon
    Lee, Sang-, II
    Hur, Jin-Wuk
    Lee, Hye-Soon
    Lee, Sang-Heon
    Kim, Jin Ran
    [J]. JOURNAL OF RHEUMATIC DISEASES, 2024, 31 (02): : 86 - 96
  • [9] Three out of four disease-modifying anti-rheumatic drug-naive rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12months: results from the FIN-ERA cohort
    Rannio, T.
    Asikainen, J.
    Hannonen, P.
    Yli-Kerttula, T.
    Ekman, P.
    Pirila, L.
    Kuusalo, L.
    Mali, M.
    Puurtinen-Vilkki, M.
    Kortelainen, S.
    Paltta, J.
    Taimen, K.
    Kauppi, M.
    Laiho, K.
    Nyrhinen, S.
    Makinen, H.
    Isomaki, P.
    Uotila, T.
    Aaltonen, K.
    Kautiainen, H.
    Sokka, T.
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2017, 46 (06) : 425 - 431
  • [10] Ixekizumab Demonstrates Consistent Efficacy Versus Adalimumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naive Psoriatic Arthritis Patients Regardless of Psoriasis Severity: 52-Week Post Hoc Results from SPIRIT-H2H
    Kristensen, Lars-Erik
    Okada, Masato
    Tillett, William
    Leage, Soyi Liu
    El Baou, Celine
    Sapin, Christophe
    Bradley, Andrew J.
    Meszaros, Gabriella
    Dutz, Jan P.
    de Vlam, Kurt
    [J]. RHEUMATOLOGY AND THERAPY, 2022, 9 (01) : 109 - 125
12